# An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

> **NCT02854436** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 289 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT02854436
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-31
- **Primary completion:** 2021-01-26
- **Final completion:** 2023-08-16
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02854436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02854436, "An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02854436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*